These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33720617)

  • 1. [A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients].
    Taieb V; Ikeoka H; Ma F; Borkowska K; Aballea S; Tone K; Hirotsu N
    Ter Arkh; 2020 Dec; 92(11):122-131. PubMed ID: 33720617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients.
    Taieb V; Ikeoka H; Ma FF; Borkowska K; Aballéa S; Tone K; Hirotsu N
    Curr Med Res Opin; 2019 Aug; 35(8):1355-1364. PubMed ID: 30810054
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
    Taieb V; Ikeoka H; Wojciechowski P; Jablonska K; Aballea S; Hill M; Hirotsu N
    Curr Med Res Opin; 2021 Feb; 37(2):225-244. PubMed ID: 33079575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis.
    Liu JW; Lin SH; Wang LC; Chiu HY; Lee JA
    JAMA Netw Open; 2021 Aug; 4(8):e2119151. PubMed ID: 34387680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
    Kumar D; Ison MG; Mira JP; Welte T; Hwan Ha J; Hui DS; Zhong N; Saito T; Katugampola L; Collinson N; Williams S; Wildum S; Ackrill A; Clinch B; Lee N
    Lancet Infect Dis; 2022 May; 22(5):718-730. PubMed ID: 35085510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials.
    Kuo YC; Lai CC; Wang YH; Chen CH; Wang CY
    J Microbiol Immunol Infect; 2021 Oct; 54(5):865-875. PubMed ID: 34020891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis.
    Zhao Y; Gao Y; Guyatt G; Uyeki TM; Liu P; Liu M; Shen Y; Chen X; Luo S; Li X; Huang R; Hao Q
    Lancet; 2024 Aug; 404(10454):764-772. PubMed ID: 39181596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid health technology assessment of the novel endonuclease inhibitor baloxavir for the treatment of influenza.
    Huang G; Tian Y; Cui W; Zhang X; Zhao Y; Liu X
    J Chemother; 2024 Jul; 36(4):267-282. PubMed ID: 37767970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T; Takazono T; Hosogaya N; Miyazaki T; Ogura E; Iwata S; Miyauchi H; Honda K; Fujiwara M; Ajisawa Y; Watanabe H; Kitanishi Y; Hara K; Mukae H
    Clin Infect Dis; 2021 Sep; 73(5):e1181-e1190. PubMed ID: 33354728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
    Tejada S; Tejo AM; Peña-López Y; Forero CG; Corbella X; Rello J
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):901-918. PubMed ID: 33861168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).
    Baker J; Block SL; Matharu B; Burleigh Macutkiewicz L; Wildum S; Dimonaco S; Collinson N; Clinch B; Piedra PA
    Pediatr Infect Dis J; 2020 Aug; 39(8):700-705. PubMed ID: 32516282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T; Takazono T; Hosogaya N; Ogura E; Fujiwara M; Miyauchi H; Ajisawa Y; Iwata S; Watanabe H; Honda K; Kitanishi Y; Hara K; Mukae H
    Clin Infect Dis; 2021 Jun; 72(11):e859-e867. PubMed ID: 33103200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
    Ando Y; Noshi T; Sato K; Ishibashi T; Yoshida Y; Hasegawa T; Onishi M; Kitano M; Oka R; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
    J Antimicrob Chemother; 2021 Jan; 76(1):189-198. PubMed ID: 33035324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection: A retrospective cohort study using an employment-based health insurance claims database in Japan.
    Hara A; Hara K; Komeda T; Ogura E; Miyazawa S; Kobayashi C; Fujiwara M; Yoshida M; Urushihara H
    Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):623-631. PubMed ID: 34881477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis.
    Shiraishi C; Kato H; Hagihara M; Asai N; Iwamoto T; Mikamo H
    J Infect Chemother; 2024 Mar; 30(3):242-249. PubMed ID: 37866622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.
    Ishiguro N; Morioka I; Nakano T; Furukawa M; Tanaka S; Kinoshita M; Manabe A
    BMC Infect Dis; 2021 Aug; 21(1):777. PubMed ID: 34372769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients.
    Macesic N; Laplante JM; Aaron JG; DiMango EA; Miko BA; Pereira MR; Reshef R; St George K
    Transpl Infect Dis; 2021 Jun; 23(3):e13542. PubMed ID: 33278052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
    Shirley M
    Drugs; 2020 Jul; 80(11):1109-1118. PubMed ID: 32601915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza.
    Abraham GM; Morton JB; Saravolatz LD
    Clin Infect Dis; 2020 Oct; 71(7):1790-1794. PubMed ID: 32020174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.